Korro to Host Virtual Analyst Day on January 27, 2026

Rhea-AI Summary

Korro (Nasdaq: KRRO) will host a virtual Analyst Day on Jan 27, 2026, 8–10 a.m. ET with management, hepatologist Bruce Scharschmidt, MD, and caregiver Michelle Dinon. Presentations will cover the unmet need in hyperammonemia, limitations of current treatments, and Korro’s development of KRRO-121, a GalNAc-conjugated construct intended to activate a biological pathway via RNA editing. The company will share preclinical data that support an anticipated regulatory filing for a first-in-human trial in H2 2026. Updates also note a GalNAc AATD program achieving >90% in vivo RNA editing and a development candidate nomination expected in H1 2026. A replay will be available for 30 days on the company website.

News Market Reaction

-2.28%

1 alert

-2.28% News Effect

On the day this news was published, KRRO declined 2.28%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Analyst Day date: January 27, 2026 Analyst Day time: 8 a.m.–10 a.m. ET RNA editing level: >90% in vivo RNA editing +3 more

6 metrics

Analyst Day date January 27, 2026 Scheduled virtual Analyst Day event

Analyst Day time 8 a.m.–10 a.m. ET Duration of virtual Analyst Day webcast

RNA editing level >90% in vivo RNA editing GalNAc-conjugated ASO intended for AATD

KRRO-121 first-in-human timing Second half of 2026 Anticipated regulatory filing for first-in-human trial

AATD candidate nomination First half of 2026 Expected development candidate nomination for GalNAc AATD program

Replay availability 30 days Length of time Analyst Day replay will be available

Market Reality Check

Price: $8.58 Vol: Volume 119,357 is below t...

low vol

$8.58 Last Close

Volume Volume 119,357 is below the 20-day average of 175,292 (relative volume 0.68). low

Technical Shares at 8.78 are trading below the 200-day MA of 19.45, reflecting a weakened longer-term trend.

Peers on Argus

KRRO’s -0.23% move contrasts with mixed peer action: ENGN up 0.98%, while FDMT, ...

KRRO’s -0.23% move contrasts with mixed peer action: ENGN up 0.98%, while FDMT, LRMR, BNTC, and IMRX are down between -0.17% and -4.28%, suggesting stock-specific dynamics rather than a clear sector rotation.

Historical Context

5 past events · Latest: Jan 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	Conference appearance	Positive	+7.8%	Participation in high-profile J.P. Morgan Healthcare Conference with webcast access.
Nov 12	Earnings and pipeline	Negative	-4.2%	Q3 results with KRRO-110 underperformance, pivot, workforce reduction, restructuring charges.
Sep 02	Conference schedule	Positive	+17.3%	Announcement of participation in multiple investor and scientific conferences on RNA editing.
Aug 12	Earnings and trial	Positive	+6.3%	Q2 results with progress in Phase 1/2a REWRITE trial and extended cash runway.
Jul 21	Orphan designation	Positive	-2.4%	EMA orphan drug designation for KRRO-110 in AATD with ongoing Phase 1/2a trial.

Pattern Detected

Conference and pipeline communication has often coincided with positive one-day moves, while some favorable clinical or designation updates have seen muted or negative reactions.

Recent Company History

Over the past six months, Korro has focused on conference visibility, clinical progress, and restructuring. Events like the J.P. Morgan and other conference appearances in Sep 2025 and Jan 2026 saw strong positive price reactions. Earnings updates in Aug and Nov 2025 combined clinical data, cash runway details, and workforce reductions, with mixed market responses. An EMA orphan drug designation in Jul 2025 drew a negative reaction. Today’s Analyst Day and pipeline update fit this pattern of active investor communication around R&D programs.

Market Pulse Summary

This announcement highlights Korro’s plan to showcase KRRO-121 and its broader RNA editing pipeline ...

Analysis

This announcement highlights Korro’s plan to showcase KRRO-121 and its broader RNA editing pipeline at a virtual Analyst Day on January 27, 2026. The event will provide context on hyperammonemia, UCD, and related programs, including a GalNAc-conjugated ASO that achieved >90% in vivo RNA editing. Historically, Korro has used conferences and webcasts to communicate clinical and strategic updates, so investors may watch for added detail on trial timing, regulatory milestones, and how pipeline priorities have evolved after prior restructuring.

Key Terms

hyperammonemia, urea cycle disorder, hepatic encephalopathy, GalNAc-conjugated, +4 more

8 terms

hyperammonemia medical

"KRRO-121 for the potential treatment of hyperammonemia, a leading clinical hepatologist"

A medical condition where the level of ammonia in the blood rises above normal, becoming toxic to the brain and other organs; symptoms can range from confusion and lethargy to coma. Investors care because therapies, diagnostics, or devices that prevent or treat this condition can affect clinical trial outcomes, regulatory approval, patient safety and market opportunity—think of it as a clogged filter in the body where fixing the filter has clear value and risk implications.

urea cycle disorder medical

"parent of a child impacted by a urea cycle disorder (UCD). Korro is developing"

A urea cycle disorder is a rare inherited condition in which the body cannot convert toxic ammonia into urea for safe excretion, so ammonia builds up in the blood and can damage the brain and other organs. For investors it signals a focused medical market: treatments and diagnostic tests can command high value, regulatory attention, and long-term care costs, much like a specialized fix for a broken household waste-disposal system.

hepatic encephalopathy medical

"patients with UCDs and hepatic encephalopathy (HE). The Analyst Day will"

A decline in brain function caused when a failing liver can no longer remove toxins from the blood, allowing substances such as ammonia to build up and interfere with thinking, coordination and alertness. Think of the liver as the body’s filter: when it clogs, toxic “smog” reaches the brain and causes confusion, sleepiness or coma. Investors watch this condition because its prevalence, available treatments, clinical-trial outcomes and regulatory decisions can materially affect the market value and prospects of healthcare companies and drug developers.

GalNAc-conjugated medical

"overview of KRRO-121, a GalNAc-conjugated construct that activates an existing"

GalNAc-conjugated describes a drug design in which therapeutic molecules are chemically linked to a simple sugar called N‑acetylgalactosamine (GalNAc) so they are efficiently carried into liver cells. For investors, this matters because the GalNAc “address label” sharply improves delivery to the liver, often allowing lower doses, fewer side effects and more predictable effects—traits that can cut development risk, shorten timelines and strengthen a drug’s commercial prospects.

antisense oligonucleotide medical

"prioritizing its GalNAc-conjugated antisense oligonucleotide (ASO) intended for"

An antisense oligonucleotide is a small piece of synthetic genetic material designed to attach to specific molecules in the body’s cells, effectively blocking or modifying how genes are expressed. This technology is important because it can be used to develop targeted treatments for certain diseases, which may influence the value of biotech companies and the broader healthcare sector. Its development reflects advances in personalized medicine and gene-based therapies.

RNA editing medical

"advancing multiple programs by leveraging the potential of RNA editing to activate"

RNA editing is a natural or engineered process that changes the molecular message copied from a gene before it is used to make a protein, like tweaking a recipe after it’s written to alter the final dish. For investors, RNA editing matters because it enables new kinds of medicines and diagnostics — promising bigger returns but also carrying technical, safety and regulatory risks that can strongly affect a biotech company’s value.

AMPKγ1 medical

"preclinical data for GalNAc-conjugated ASO targeting AMPKγ1 for longevity and"

AMPKγ1 is the gamma-1 regulatory subunit of the AMPK complex, the cellular “energy sensor” protein that helps cells detect low energy and switch on pathways to restore balance. For investors, it matters because this subunit is a key control point for metabolism and cell survival, so drugs or tests that affect or measure AMPKγ1 can signal therapeutic potential and commercial opportunity in metabolic, cardiac and oncology areas—similar to a thermostat that guides how a system reacts and how valuable interventions might be.

amyotrophic lateral sclerosis (ALS) medical

"ASO modulating TDP-43 intended for amyotrophic lateral sclerosis (ALS)."

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that damages nerve cells responsible for controlling voluntary muscles, leading to muscle weakness, loss of movement, and eventually paralysis. It matters to investors because health-related research, treatments, and biotech companies working on ALS can influence stock markets and create opportunities or risks within the healthcare sector.

AI-generated analysis. Not financial advice.

- Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia, a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing perspectives on living with urea cycle disorder -

CAMBRIDGE, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that the company will host a virtual Analyst Day on Tuesday, January 27, 2026, from 8 a.m. – 10 a.m. ET, with members of the Korro management team, Bruce Scharschmidt, MD, hepatologist and former Chief Medical Officer of Hyperion Therapeutics, and Michelle Dinon, parent of a child impacted by a urea cycle disorder (UCD).

Korro is developing KRRO-121 for the potential treatment of hyperammonemia in patients with UCDs and hepatic encephalopathy (HE). The Analyst Day will feature an overview of these diseases delivered by Dr. Scharschmidt, Mrs. Dinon’s perspective of raising a child with UCD, and Korro’s insights into the development of KRRO-121.

Speakers will include:

• Ram Aiyar, PhD, MBA, Chief Executive Officer and President, Korro
• Loic Vincent, PhD, Chief Scientific Officer, Korro
• Todd Chappell, MBA, Chief Operating Officer, Korro
• Bruce Scharschmidt, MD, Hepatologist and UCD / HE expert
• Michelle Dinon, UCD parent
  
  

Attendees will learn about the deep unmet need in hyperammonemia, limitations of the current treatment options, and associated healthcare burden. Korro management will provide an overview of KRRO-121, a GalNAc-conjugated construct that activates an existing biological pathway by creating a de novo variant with therapeutic potential in patients with hyperammonemia. The company also will share preclinical data supporting KRRO-121’s anticipated regulatory filing for the first-in-human trial in the second half of 2026.

"Our Analyst Day provides an important opportunity to increase awareness of ammonia-driven diseases, which are challenging to live with and have substantial unmet therapeutic need. Michelle will share her perspectives on the impact these challenges impose on the day-to-day lives of people with UCD,” said Ram Aiyar. “We expect that pairing her personal experience with Dr. Scharschmidt’s clinical perspectives and our team’s growing body of evidence supporting the potential of KRRO-121 as a transformative therapy will provide a compelling rationale for advancing this program into the clinic later this year. KRRO-121 represents a first step in modulating protein function by stabilizing an intracellular protein through RNA editing."

To register for the Analyst Day webcast please use this link. Following the presentation, a replay of the event will be available for 30 days on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com.

Korro Pipeline Updates

At last week's J.P. Morgan Healthcare Conference, Dr. Aiyar provided a company update, highlighting the momentum across Korro’s pipeline. The company is advancing multiple programs by leveraging the potential of RNA editing to activate biological pathways. In addition to KRRO-121 targeting hyperammonemia, the company is prioritizing its GalNAc-conjugated antisense oligonucleotide (ASO) intended for Alpha-1 Antitrypsin Deficiency (AATD), which achieved >90% in vivo RNA editing —the highest reported to date. Korro expects to nominate a development candidate for this next-generation GalNAc AATD program in the first half of 2026. Additionally, the company is further expanding the potential of its RNA editing platform, OPERA^®, with promising preclinical data for GalNAc-conjugated ASO targeting AMPKγ1 for longevity and ASO modulating TDP-43 intended for amyotrophic lateral sclerosis (ALS).

About Korro

Korro is a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.

About Hyperammonemia and KRRO-121

Hyperammonemia is due to insufficient clearance of ammonia from the blood stream. It manifests in multiple indications such as urea cycle disorders (UCD) and hepatic encephalopathy (HE). UCD are rare inborn errors of metabolism involving deficiencies of enzymes required for ureagenesis. The absence or deficiency of any of the urea cycle enzymes results in increased ammonia in the blood to dangerous levels. HE is a neuropsychiatric complication of liver disease characterized by cognitive dysfunction and altered consciousness. HE is primarily caused by the liver’s inability to detoxify ammonia. This leads to ammonia accumulating in the bloodstream and crossing the blood-brain barrier, causing brain dysfunction that ranges from subtle cognitive impairment to severe confusion and coma, significantly impacting patients' quality of life. KRRO-121 is an RNA-editing oligonucleotide conjugated with GalNAc for the potential treatment of hyperammonemia in patients with UCD of any mutational background in adults and adolescents as well as patients with HE. Utilizing Korro’s proprietary OPERA^® platform, KRRO-121 is designed to stabilize a critical enzyme involved in reducing ammonia levels.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, express or implied statements regarding expectations, hopes, beliefs, intentions or strategies of Korro regarding the future including, without limitation, express or implied statements regarding: the timing of the regulatory filing for KRRO-121; the potential of Korro’s GalNAC-conjugated programs targeting the liver, including KRRO-121 as a treatment for hyperammonemia for patients with UCDs and HE and GalNAc delivery for AATD patients; timing of nominating a development candidate for Korro’s GalNAc-conjugated program for AATD; among others. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking. Forward-looking statements are based on current expectations and assumptions that, while considered reasonable are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including risks associated with pre-clinical studies and conducting clinical trials; risks associated with validating in clinical trials observations from pre-clinical studies; risks associated with collaborating with third parties; other risks associated with protecting intellectual property; as well as risks associated with general economic conditions; and other risks and uncertainties indicated from time to time in Korro’s filings with the SEC, including Part I Item 1A. “Risk Factors” in Korro’s Quarterly Report on Form 10-Q filed with the SEC on the date hereof, as such may be amended or supplemented by its other filings with the SEC. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by law, Korro does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Korro.

Korro Bio Contact Information 

Investor & Media Contact
IR@korrobio.com

FAQ

When is Korro's virtual Analyst Day for KRRO (KRRO) and how long is it?

The Analyst Day is on January 27, 2026 from 8:00–10:00 a.m. ET.

Who are the key presenters at Korro's Jan 27, 2026 Analyst Day (KRRO)?

Presenters include CEO Ram Aiyar, CSO Loic Vincent, COO Todd Chappell, hepatologist Dr. Bruce Scharschmidt, and caregiver Michelle Dinon.

What will Korro announce about KRRO-121 at the Analyst Day (KRRO)?

Korro will present preclinical data on KRRO-121 and discuss plans supporting a regulatory filing for a first-in-human trial in H2 2026.

What preclinical progress did Korro report for its AATD program (KRRO)?

Korro reported its GalNAc-conjugated AATD ASO achieved >90% in vivo RNA editing and expects to nominate a development candidate in H1 2026.

How can investors access Korro's Analyst Day webcast and replay (KRRO)?

Investors can register via the company's webcast link; a replay will be available for 30 days on the Events & Presentations page of Korro's investor website.

What clinical and patient perspectives will be included in Korro's Analyst Day (KRRO)?

The program includes a clinical overview of ammonia-driven diseases from Dr. Scharschmidt and a caregiver perspective from Michelle Dinon about living with urea cycle disorder.